|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wei WI and Sham JS: Nasopharyngeal
carcinoma. Lancet. 365:2041–2054. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chang JT, See LC, Liao CT, Ng SH, Wang CH,
Chen IH, Tsang NM, Tseng CK, Tang SG and Hong JH: Locally recurrent
nasopharyngeal carcinoma. Radiother Onco1. 54:135–142. 2000.
View Article : Google Scholar
|
|
4
|
Stoker SD, van Diessen JNA, de Boer JP,
Karakullukcu B, Leemans CR and Tan IB: Current treatment options
for local residual nasopharyngeal carcinoma. Curr Treat Options
Oncol. 14:475–491. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Qiu S, Lin S, Tham IW, Pan J, Lu J and Lu
JJ: Intensity-modulated radiation therapy in the salvage of locally
recurrent nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys.
83:676–683. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lee AW, Sze WM, Au JS, Leung SF, Leung TW,
Chua DT, Zee BC, Law SC, Teo PM, Tung SY, et al: Treatment results
for nasopharyngeal carcinoma in the modern era: The Hong Kong
experience. Int J Radiat Oncol Biol Phys. 61:1107–1116. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yeh SA, Tang Y, Lui CC, Huang YJ and Huang
EY: Treatment outcomes and late complications of 849 patients with
nasopharyngeal carcinoma treated with radiotherapy alone. Int J
Radiat Oncol Biol Phys. 62:672–679. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Baujat B, Audry H, Bourhis J, Chan AT,
Onat H, Chua DT, Kwong DL, Al-Sarraf M, Chi KH, Hareyama M, et al:
Chemotherapy in locally advanced nasopharyngeal carcinoma: An
individual patient data meta-analysis of eight randomized trials
and 1753 patients. Int J Radiat Oncol Biol Phys. 64:47–56. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Vermorken JB and Specenier P: Optimal
treatment for recurrent/metastatic head and neck cancer. Ann Oncol.
21 Suppl 7:vii252–vii261. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bianco C, Tortora G, Bianco R, Caputo R,
Veneziani BM, Caputo R, Damiano V, Troiani T, Fontanini G, Raben D,
et al: Enhancement of antitumor activity of ionizing radiation by
combined treatment with the selective epidermal growth factor
receptor-tyrosine kinase inhibitor ZD1839 (Iressa). Clin Cancer
Res. 8:3250–3258. 2002.PubMed/NCBI
|
|
11
|
Ai Z, Wang J, Wang Y, Lu L, Tong J and
Teng Y: Overexpressed epidermal growth factor receptor
(EGFR)-induced progestin insensitivity in human endometrial
carcinoma cells by the EGFR/mitogen-activated protein kinase
signaling pathway. Cancer. 116:3603–3613. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Pfister DG, Su YB, Kraus DH, Wolden SL,
Lis E, Aliff TB, Zahalsky AJ, Lake S, Needle MN and Shaha AR:
Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy
for locoregionally advanced squamous cell head and neck cancer: A
pilot phase II study of a new combined-modality paradigm. J Clin
Oncol. 24:1072–1078. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Du Y, Peyser ND and Grandis JR:
Integration of molecular targeted therapy with radiation in head
and neck cancer. Pharmacol Ther. 142:88–98. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bonner JA, Harari PM, Giralt J, Azarnia N,
Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, et al:
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head
and neck. N Engl J Med. 354:567–578. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bonner JA, Harari PM, Giralt J, Cohen RB,
Jones CU, Sur RK, Raben D, Baselga J, Spencer SA, Zhu J, et al:
Radiotherapy plus cetuximab for locoregionally advanced head and
neck cancer: 5-year survival data from a phase 3 randomised trial,
and relation between cetuximab-induced rash andsurvival. Lancet
Oncol. 11:21–28. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Vermorken JB, Mesia R, Rivera F, Remenar
E, Kawecki A, Rottey S, Erfan J, Zabolotnyy D, Kienzer HR, Cupissol
D, et al: Platinum-based chemotherapy plus cetuximab in head and
neck cancer. N Engl J Med. 359:1116–1127. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Cohen RB: Current challenges and clinical
investigations of epidermal growth factor receptor (EGFR) and ErbB
family-targeted agents in the treatmentof head and neck squamous
cell carcinoma (HNSCC). Cancer Treat Rev. 40:567–577. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Edge SB and Compton CC: The American joint
committee on cancer: The 7th edition of the AJCC cancer staging
manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Huang XQ, Chen X, Xie XX, Zhou Q, Li K, Li
S, Shen LF and Su J: Co-expression of CD147 and GLUT-1 indicates
radiation resistance and poor prognosis in cervical squamous cell
carcinoma. Int J Clin Exp Pathol. 7:1651–1666. 2014.PubMed/NCBI
|
|
20
|
Zhao Y, Shen L, Chen X, Qian Y, Zhou Q,
Wang Y, Li K, Liu M, Zhang S and Huang X: High expression of PKM2
as a poor prognosis indicatoris associated with radiation
resistance in cervical cancer. Histol Histopathol. 30:1313–1320.
2015.PubMed/NCBI
|
|
21
|
International Commission on Radiation
Units and Measurements (ICRU), . ICRU Report: Prescribing,
recording, and reporting photon beam therapy. 50. ICRU; Bethesda,
MD: 1993
|
|
22
|
International Commission on Radiation
Units and Measurements (ICRU), . ICRU Report: Prescribing,
recording, and reporting photon beam therapy. 62. ICRU; Bethesda,
MD: 1999, (supplement to ICRU report 50).
|
|
23
|
Zhao Y and Shen L, Huang X, Jing D, Huang
D, Fu J, Li Z, Zhang G and Shen L: High expression of Ki-67 acts a
poor prognosis indicator in locally advanced nasopharyngeal
carcinoma. Biochem Biophys Res Commun. 494:390–396. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhou Q, He Y, Zhao Y, Wang Y, Kuang W and
Shen L: A study of 358 cases of locally advanced nasopharyngeal
carcinoma receiving intensity-modulated radiation therapy:
Improving the seventh edition of the American joint committee on
cancer T-staging system. Biomed Res Int.
2017:14196762017.PubMed/NCBI
|
|
25
|
Radiation Therapy Oncology Group, . A
Phase II Study of Intensity Modulated Radiation Therapy
(IMRT)+/− Chemotherapy for Nasopharyngeal Cancer. RTOG
protocol 0225. 2014, https://www.rtog.org
|
|
26
|
He Y, Zhou Q, Shen L, Zhao Y, Lei M, Wei
R, Shen L and Cao S: A retrospective study of the prognostic value
of MRI-derived residual tumors at the end ofintensity-modulated
radiotherapy in 358 patients with locally-advanced nasopharyngeal
carcinoma. Radiat Oncol. 10:892015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Liu X, Liu LZ, Mao YP, Chen L, Tang LL,
Zhou GQ, Sun Y, Yue D, Lin AH, Li L and Ma J: Prognostic value
ofmagnetic resonance imaging-detected cranial nerve invasion in
nasopharyngeal carcinoma. Br J Cancer. 110:1465–1471. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hsu HC, Chen CL, Hsu MM, Lynn TC, Tu SM
and Huang SC: Pathology of nasopharyngeal carcinoma. Proposal of a
new histologic classification correlated with prognosis. Cancer.
59:945–951. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yang S, Chen J, Guo Y, Lin H, Zhang Z,
Feng G, Hao Y, Cheng J, Liang P, Chen K, et al: Identification of
prognostic biomarkers for response to radiotherapy by DNA
microarray in nasopharyngeal carcinoma patients. Int J Oncol.
40:1590–1600. 2012.PubMed/NCBI
|
|
30
|
Little SE, Bax DA, Rodriguez-Pinilla M,
Natrajan R, Messahel B, Pritchard-Jones K, Vujanic GM, Reis-Filho
JS and Jones C: Multifaceted dysregulation of the epidermal growth
factor receptor pathway in clear cell sarcoma of the kidney. Clin
Cancer Res. 13:4360–4364. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ekstrand AJ, James CD, Cavenee WK, Seliger
B, Pettersson RF and Collins VP: Genes for epidermal growth factor
receptor, transforming growth factor alpha, and epidermal growth
factor and their expression in human gliomas in vivo. Cancer Res.
51:2164–2172. 1991.PubMed/NCBI
|
|
32
|
Qi DL, Cui Y, Wang QS, Huang CB, Xu J,
Yang YZ, Xin L, Tian Y and Qi XA: A clinical trail on docetaxel and
carboplatin therapy with or without nimotuzumab for the treatment
of advanced nonsmall cell lung cancer. J Cancer Res Ther. 11 Suppl
1:C32–C37. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Shin DM, Ro JY, Hong WK and Hittelman WN:
Dysregulation of epidermal growth factor receptor expression in
premalignant lesions during head and neck tumorigenesis. Cancer
Res. 54:3153–3159. 1994.PubMed/NCBI
|
|
34
|
Pan J, Tang T, Xu L, Lu JJ, Lin S, Qiu S,
Chen G and K Tham IW: Prognostic significance of expression of
cyclooxygenase-2, vascular endothelial growth factor, and epidermal
growth factor receptor in nasopharyngeal carcinoma. Head Neck.
35:1238–1247. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ma BB, Poon TC, To KF, Zee B, Mo FK, Chan
CM, Ho S, Teo PM, Johnson PJ and Chan AC: Prognostic significance
of tumor angiogenesis, Ki67, p53 oncoprotein, epidermal growth
factor receptor and HER2 receptor protein expression in
undifferentiated nasopharyngeal carcinoma-a prospective study. Head
Neck. 25:864–872. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Soo R, Putti T, Tao Q, Goh BC, Lee KH,
Kwok-Seng L, Tan L and Hsieh WS: Overexpression of cyclooxygenase-2
in nasopharyngeal carcinoma and association with epidermal growth
factor receptor expression. Arch Otolaryngol Head Neck Surg.
131:147–152. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Pan J, Kong L, Lin S, Chen G, Chen Q and
Lu JJ: The clinical significance of coexpression of
cyclooxygenases-2, vascular endothelial growth factors, and
epidermal growth factor receptor in nasopharyngeal carcinoma.
Laryngoscope. 118:1970–1975. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Lee SC, Lim SG, Soo R, Hsieh WS, Guo JY,
Putti T, Tao Q, Soong R and Goh BC: Lack of somatic mutations in
EGFR tyrosine kinase domain in hepatocellular and nasopharyngeal
carcinoma. Pharmacogenet Genomics. 16:73–74. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zhang ZC, Fu S, Wang F, Wang HY, Zeng YX
and Shao JY: Oncogene mutational profile in nasopharyngeal
carcinoma. Onco Targets Ther. 7:457–467. 2014.PubMed/NCBI
|
|
40
|
Zuo Q, Shi M, Chen J and Liao W: The Ras
signaling pathway mediates cetuximab resistance in nasopharyngeal
carcinoma. Biomed Pharmacother. 65:168–174. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Fernández-Medarde A and Santos E: Ras in
cancer and developmental diseases. Genes Cancer. 2:344–358. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Bozec A, Etienne-Grimaldi MC, Fischel JL,
Sudaka A, Toussan N, Formento P and Milano G: The mTOR-targeting
drug temsirolimus enhances the growth-inhibiting effects of the
cetuximabbevacizumab-irradiation combination on head and neck
cancer xenografts. Oral Oncol. 47:340–344. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Chung CH, Wang H, Tsottles N, Gourin CG,
Agrawal N, Molinolo A, Gutkind S, Forastiere AA and Marur S: A
phase I study of everolimus in combination with cetuximab and
cisplatin as first-line therapy in recurrent and metastatic (R/M)
head and neck squamous cell carcinoma (HNSCC). J Clin Oncol Oncol
Clin Oncol. 30 Suppl:2012.
|
|
44
|
Argiris A, Ohr J, Kubicek GJ, Duvvuri U,
Heron DE, Kotsakis AP, Spencer C, Kim S, Grandis JR, Johnson JT, et
al: Phase II randomized trial of radiotherapy (RT), cetuximab (E),
and pemetrexed (Pem) with or without bevacizumab (B) in locally
advanced squamous cell carcinoma of the head and neck (SCCHN). J
Clin Oncol. 31 Suppl:S6043. 2013.
|
|
45
|
Xu M, Mizoguchi I, Morishima N, Chiba Y,
Mizuguchi J and Yoshimoto T: Regulation of antitumor immune
responses by the IL-12 family cytokines, IL-12, IL-23, and IL-27.
Clin Dev Immunol. 2010:8324542010. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Yoo DS, Kirkpatrick JP, Craciunescu O,
Broadwater G, Peterson BL, Carroll MD, Clough R, MacFall JR, Hoang
J, Scher RL, et al: Prospective trial of synchronous bevacizumab,
erlotinib, and concurrent chemoradiation in locally advanced head
and neck cancer. Clin Cancer Res. 18:1404–1414. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Argiris A, Kotsakis AP, Hoang T, Worden
FP, Savvides P, Gibson MK, Gyanchandani R, Blumenschein GR Jr, Chen
HX, Grandis JR, et al: Cetuximab and bevacizumab: Preclinical data
and phase II trial in recurrent or metastatic squamous cell
carcinoma of the head and neck. Ann Oncol. 24:220–225. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Liu MT, Chen MK, Huang CC and Huang CY:
Prognostic value of molecular markers and implication for molecular
targeted therapies in nasopharyngeal carcinoma: An update in an era
of new targeted molecules development. World J Oncol. 6:243–261.
2015. View Article : Google Scholar : PubMed/NCBI
|
